Co-trimoxazole for idiopathic pulmonary fibrosis: time for TIPAC-2?
نویسندگان
چکیده
منابع مشابه
Co-trimoxazole for idiopathic pulmonary fibrosis: time for TIPAC-2?
Idiopathic pulmonary fibrosis (IPF) is a devastating disease with an average life expectancy from diagnosis of 2.5 years with 5 year survival of between 20% and 40%. Currently there are no therapies proven to reduce mortality and only one drug, pirfenidone, is licensed for use in Europe that may slow the progression of the disease. Cleary developing effective therapy for IPF is a major unmet he...
متن کاملAuthor's response: co-trimoxazole treatment in idiopathic pulmonary fibrosis.
We thank Neto et al for their comments on our paper and for reiterating the points contained within it. ‘The survival benefit conferred by co-trimoxazole, if real, could be due to its antimicrobial activity as there was a significant reduction in the number of infections in the group receiving active treatment’, and this is likely to occur more frequently in patients receiving immunosuppressive...
متن کاملThe Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial
BACKGROUND We hypothesise, based upon the findings from our previous trial, that the addition of co-trimoxazole to standard therapy is beneficial to patients with moderate to severe idiopathic pulmonary fibrosis (IPF). We aim to investigate this by assessing unplanned hospitalisation-free survival (defined as time from randomisation to first non-elective hospitalisation, lung transplant or deat...
متن کاملPulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis: A Chance for a Multidisciplinary Treatment Approach
Background and Objectives: Idiopathic pulmonary fibrosis (IPF) is characterized by progressively worsening lung function, ventilation capacity, dyspnea, and finally reduced exercise intolerance. All of these have a significant negative impact on functional capacity and quality of life. In this study, we aim to evaluate the effects of pulmonary rehabilitation (PR) in IPF and assess the predictor...
متن کاملTreating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a fatal condition with limited treatment options. However, in a previous small study, co-trimoxazole was found to be beneficial. METHODS In a double-blind multicentre study, 181 patients with fibrotic idiopathic interstitial pneumonia (89% diagnosed as definite/probable IPF) were randomised to receive co-trimoxazole 960 mg twice daily or place...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Thorax
سال: 2012
ISSN: 0040-6376,1468-3296
DOI: 10.1136/thoraxjnl-2012-202531